Hasby Eiman Adel, Saied Eman M
The Department of Pathology, Faculty of Medicine, Tanta University.
J Egypt Natl Canc Inst. 2008 Jun;20(2):158-67.
Topoisomerase II a (Topo II a) and Her-2/neu are two important targeted therapeutic molecules. The immunohistochemical expression of both of them has not been widely studied in prostatic carcinoma and benign prostatic hyperplasia (BPH). The aim of this study was to evaluate the immunohistochemical expression of Topo II a and Her-2/neu in prostatic carcinoma and BPH and compare the expression patterns of both genes in cases of prostatic carcinoma in relation to Gleason score and hormonal status.
Paraffin blocks of 30 cases of prostatic carcinoma (categorized by Gleason score and hormonal status) and 5 cases of BPH presented to the Department of Pathology, Faculty of Medicine, Tanta University during the period from 2005 to 2008 were retrieved from the files. The immunohistochemical expression of Topo II a and Her-2/neu antibodies in the above-mentioned diagnostic categories was investigated and compared. The percentage of nuclei staining for Topo II a was semiquantitated; overexpression was defined as >or=5% nuclear staining. Her-2/neu immunoreactivity was scored from 0 to 3 + depending on membrane staining intensity and pattern.
The expression of Topo II a varied significantly among the different studied groups (p<0.001). Topo II a expression increased significantly with increased Gleason score in prostatic carcinoma (p=0.001). Its expression in both moderately and poorly differentiated carcinomas was significantly higher than in BPH (p=0.005 and 0.002 respectively); however the difference between its expression in well-differentiated carcinoma and in BPH was statistically insignificant (p=0.171). Her-2/neu expression was higher in prostatic carcinoma than in BPH, however the difference did not reach the level of statistical significance (p=0.084). Also, the increase in its expression within prostatic carcinoma cases with increased Gleason score was statistically insignificant (p=0.100). There was a significant correlation between Topo II a and Her-2/neu expression (p=0.008, r=0.478). Hormone resistant carcinomas showed higher expression of Topo II a and Her- 2/neu than carcinomas with no hormone treatment, however, the differences were statistically insignificant (p=0.594 and 0.667 respectively).
Topo II a expression was significantly higher in poorly differentiated and moderately differentiated prostatic carcinoma compared to BPH. There was a significant increase in Topo II a expression with increased Gleason score. Her-2/neu expression was higher in prostatic carcinoma than in BPH, however the difference did not reach the level of statistical significance and the increase in its expression with increased Gleason score was also statistically insignificant. Topo II a and Her-2/neu were co-expressed significantly. Hormone resistant carcinomas showed higher expression of both markers, however, the differences were statistically insignificant. The latter finding may have important therapeutic implications, however, further large scale studies are required for confirmation.
Topo II a - Her-2/neu - Prostatic carcinoma - BPH.
拓扑异构酶IIα（Topo IIα）和Her-2/neu是两种重要的靶向治疗分子。它们在前列腺癌和良性前列腺增生（BPH）中的免疫组化表达尚未得到广泛研究。本研究的目的是评估Topo IIα和Her-2/neu在前列腺癌和BPH中的免疫组化表达，并比较两者在前列腺癌病例中的表达模式与Gleason评分和激素状态的关系。
从坦塔大学医学院病理学系2005年至2008年期间存档的文件中检索出30例前列腺癌（按Gleason评分和激素状态分类）和5例BPH的石蜡块。研究并比较上述诊断类别中Topo IIα和Her-2/neu抗体的免疫组化表达。对Topo IIα的细胞核染色百分比进行半定量分析；过表达定义为核染色≥5%。根据膜染色强度和模式，将Her-2/neu免疫反应性评分为0至3+。
不同研究组之间Topo IIα的表达差异有统计学意义（p<0.001）。在前列腺癌中，Topo IIα表达随Gleason评分增加而显著升高（p=0.001）。其在中分化和低分化癌中的表达均显著高于BPH（分别为p=0.005和0.002）；然而，其在高分化癌和BPH中的表达差异无统计学意义（p=0.171）。Her-2/neu在前列腺癌中的表达高于BPH，但差异未达到统计学意义水平（p=0.084）。此外，在前列腺癌病例中，其表达随Gleason评分增加的升高也无统计学意义（p=0.100）。Topo IIα和Her-2/neu表达之间存在显著相关性（p=0.008，r=0.478）。激素抵抗性癌中Topo IIα和Her-2/neu的表达高于未接受激素治疗的癌，但差异无统计学意义（分别为p=0.594和0.667）。
与BPH相比，低分化和中分化前列腺癌中Topo IIα表达显著更高。Topo IIα表达随Gleason评分增加而显著升高。Her-2/neu在前列腺癌中的表达高于BPH，但差异未达到统计学意义水平，且其表达随Gleason评分增加的升高也无统计学意义。Topo IIα和Her-2/neu显著共表达。激素抵抗性癌中两种标志物的表达更高，但差异无统计学意义。后一发现可能具有重要的治疗意义，然而，需要进一步的大规模研究来证实。
Topo IIα - Her-2/neu - 前列腺癌 - BPH
